GlassScriptPhysician profile
Jazmin A Logendra
NPI 1689873465
$3,084.97
in general payments reported to CMS, 2019-2025
15 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2021: $195 · 2022: $233 · 2023: $111 · 2024: $374 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Travel and Lodging: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.10 |
| Travel and Lodging | $821.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,499.12 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $364.89 | 2021-2025 | Precision7, Tryptyr, Eysuvis |
| Biotissue Holdings INC. | $218.48 | 2025 | |
| Harrow Eye, LLC | $187.55 | 2024-2025 | Vevye |
| Dompe US, INC. | $134.01 | 2025 | Oxervate |
| Shire North American Group INC | $131.68 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $123.64 | 2024-2025 | Xdemvy |
| Abbvie INC. | $104.20 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $81.12 | 2022-2025 | Infuse |
| Oyster Point Pharma, INC. | $67.96 | 2023-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $58.30 | 2021-2025 | |
| Abb Con-Cise Optical Group LLC | $41.65 | 2022-2023 | Spectacle Lenses, Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.39 | 2021 | |
| Amgen INC. | $20.23 | 2024 | Tepezza |
| Kala Pharmaceuticals, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jazmin Logendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.